← About this guide

PRINTABLE SUMMARY

Before You Spend Money on Peptides

A clear starting point for evaluating peptide claims.

1 sectionsEvidence: October 7, 2026 selection; October 27, 2026 annotated source checks; no new literature search

AI-assisted editorial edition · Independent clinical review pending.

Before you read

Educational source reading for adults, not diagnosis, prescription or a personal treatment plan. Do not start, stop or change treatment because of this guide. Discuss treatment, medicines and product questions with a qualified clinician and pharmacist.

What this edition can and cannot answer

A selected-source introduction to matching studies to product claims and preparing informed questions

  • A study must match the actual substance, route, population, comparator and outcome before its conclusion can support a claim.
  • Analytical quality, clinical benefit, safety and regulatory status answer different questions. A worksheet does not establish that a treatment is suitable for you.
  • The selected-source introduction retains its October 7, 2026 evidence scope with October 27 source annotations; independent review remains pending.

SECTION 01

Before you buy: your claim-reading sheet

Write your question in one sentence: “For someone with my condition, does this exact treatment improve this outcome compared with the alternatives?” You do not need technical language to ask it.

CheckQuestion
MoleculeWas the exact substance studied?
RouteWas it used in the same way?
PopulationWho or what was studied?
ComparisonWhat was it compared with?
OutcomeWas the advertised result measured?

A product-quality certificate cannot establish a clinical benefit. A short report without recorded side effects cannot establish safety for everyone. Compounded drugs are not FDA-approved. [1] [2]

Take one clear question to your appointment

Use these prompts to prepare questions. Notes stay on this page; print this view to keep them.

FOLLOW THE EVIDENCE

Sources and reading limits

  1. FDA. Evaluation of BPC-157-related bulk drug substances (2026)

    Regulatory assessment

    PDF pp. 8-9 and safety/conclusion sections; advisory briefing, not a final approval

  2. FDA. Compounding and the FDA: Questions and Answers

    Regulatory explanation

    Sections: compounded drugs, approval and risks; official snapshot checked 27 October 2026; content current 16 September 2025

  3. 0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution in Neurotrophic Keratopathy (2023)

    Randomized human eye-disease trial

    Physical PDF pp. 3-5 and 11-14; Table 2 p. 5; registry/supplement checked 27 October 2026; day-36 conflict unresolved

Edition and corrections

Web reading edition: 4 November 2026. Manuscript prepared: 2026-11-04. This web-format update does not represent a new literature search or completed clinical review.

Edition: before-you-buy-2026-11-04-format-draft

Scientific interpretation, source-access limits and independent review are separate from publication of this reading view.

Report a correction →

Explore all consumer guides